Lipopolysaccharide (LPS) from E.coli Serotype O55:B5
Catalog #: HC4045
Quantity: 1 mg
Humans as well as other vertebrates are often exposed to lipopolysaccharide (LPS), for instance via enterobacteria. LPS responses are mediated via Toll-like receptor 4 (TLR4). TLRs are conserved pattern recognition receptors which recognize and respond to molecules derived from bacterial, viral and fungal pathogens, such as LPS from the outer membrane of Gram negative bacteria. Recognition of LPS occurs largely by the TLR4/MD2/CD14 complex, expressed among others by macrophages and dendritic cells. The acute phase LPS-binding protein (LBP) recognizes the lipid A part of LPS and catalyses the monomeric LPS transfer to CD14. This facilitates the LPS transfer to TLR4/MD2. All immunological activity of LPS is exclusively dependent upon the presence of TLR4 as determined by the usage of the corresponding control cells, where TLR4 is missing. Recognition of LPS triggers a cascade of adverse systemic responses and organ failure (septic shock). LPS is a key component of the cell wall of gram negative bacteria (S-form LPS). The molecule consist of three structural regions: the O-polysaccharide chain made up of repeating oligosaccharide units, the core oligosaccharide and- Lipid A. The latter is responsible for the endotoxic activity of the entire molecule. R-form LPS synthesized by the so-called rough (R) mutants of gram-negative bacteria lacks the O-specific chain. Furthermore, the core-oligosaccharide may be present in different degrees of completion, depending on the class (Ra to Re) to which the mutant belongs. LPS from wild type bacteria are always a highly heterogeneous mixtures of S-form LPS molecules containing 1 to over 50 repeating oligosaccharide units and contain a varying proportion of R-form molecules. R-form LPS and lipid A, but not S-form LPS, are capable of inducing TNF-; responses also in the absence of CD14. S- and R-form LPS show marked differences in the kinetics of their blood clearance and cellular uptake as well as in the ability to induce oxidative burst in human granulocytes and to activate the host complement system.
|Product type||LPS and ligands|
|Purity||≥99.9 %. No detectable TLR4 independent activity: potent standardized TLR4-specific agonist|
|Formulation||1 mg (1mg/ml) ready-to-use in aqueous solution in ultra-pure endotoxin-free double-distilled sterile water. At least 5x105 EU/mg.|
|Storage and stability||Product should be stored at 4 °C. Do not freeze. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.|
|Precautions||For research use only. Not for use in or on humans or animals or for diagnostics. Use of this product for human or animal testing is extremely hazardous and may result in disease, severe injury, or death.
It is the responsibility of the user to comply with all local/state and federal rules in the use of this product. Hycult Biotech is not responsible for any patent infringements that might result from the use or derivation of this product. Material Safety Data Sheet: This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, inhale or get in the blood stream.
Use:Prepare diluted LPS working solutions just prior to use, keep sterile. The supplied solution is cell culture-grade. Optimal concentration is dependent upon cell type, species, desired activation and analysis: 0.01 -1.0 μg/ml. Does not activate any TLR other than TLR4 as tested in relevant biological systems.